Allena Pharmaceuticals, Inc. (ALNAQ) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Newton, MA, アメリカ.
ALNAQ を有する IPO日 2017-11-02, 12 名の正社員, に上場 Other OTC, 時価総額 $122.00.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
